Corporate Restructuring, Recognitions, Drug Approvals, Mergers and Stock Price Movements - Research Report on Agilent, UnitedHealth, Onyx, Alexion, and Opko Health Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, September 24, 2013 NEW YORK, September 24, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Agilent Technologies Inc. (NYSE: A), UnitedHealth Group Inc. (NYSE: UNH), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), and Opko Health Inc. (NYSE: OPK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Agilent Technologies Inc. Research Report On September 19, 2013, Agilent Technologies Inc. (Agilent) announced that it plans to separate into two publicly traded companies: one in life sciences, diagnostics, and applied markets (LDA) that will keep the Agilent name, while the other company will be made up of Agilent's portfolio of electronic measurement (EM) products. Agilent stated that the transaction aims for strategic and operational advancements and improvements of both businesses while also allows management to focus specifically on the customers of their respective companies. According to the Company, Agilent shareholders will receive a pro rata distribution of shares in the new EM Company via tax-free spinoff. The Company expects the transaction to be completed by the end of 2014, subject to the satisfaction of closing conditions. Agilent informed that the spinoff will have effect on its guidance for FY 2013, though the Company expects to incur one-time charges related to the transaction during the periods preceding the separation, to be quantified at a later date. The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-19/A] -- UnitedHealth Group Inc. Research Report On September 19, 2013, UnitedHealth Group Inc. (UnitedHealth) announced that the Association of State and Territorial Health Officials (ASTHO) and United Health Foundation named the Minnesota Department of Health (MDH) as the 2013 winner of the America's Health Rankings Champion Award. According to United Health, the award honors a state or territorial health department that uses data from the rankings to improve its state's health outcomes, including addressing health disparities, and to build relationships with local health departments and other partners. Minnesota Commissioner of Health Edward Ehlinger, M.D., MSPH, said, "The Minnesota Department of Health uses the Rankings to inform and motivate our department programs and community partners in a shared effort to make Minnesota the healthiest state possible." The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-19/UNH] -- Onyx Pharmaceuticals Inc. Research Report On September 18, 2013, Onyx Pharmaceuticals Inc. (Onyx) announced that the waiting period in connection with Amgen's proposed acquisition of Onyx, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), was terminated early on September 18, 2013 by United States Federal Trade Commission as against its prior scheduled date of September 23, 2013. Onyx stated that the termination of the HSR meets one of the conditions to fulfill the tender offer and amongst one of the other conditions that need to be satisfied is a minimum tender of at least a majority of outstanding Onyx shares on a fully diluted basis. According to Onyx, the tender offer under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash, is scheduled to expire at 12:00 midnight, New York City time, on October 1, 2013, unless it is extended pursuant to, and in accordance with the terms of the merger agreement between Amgen and Onyx. The Full Research Report on Onyx Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-19/ONXX] -- Alexion Pharmaceuticals, Inc. Research Report On September 13, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Soliris (eculizumab) for the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening, ultra-rare disorder which can progressively damage vital organs, leading to stroke, heart attack, and kidney failure. According to Alexion, the drug has already secured approval in Japan for the treatment of paroxysmal hemoglobinuria (PNH), another severe and ultra-rare disease. Prof. Motoshi Hattori, Professor and Director of the Department of Pediatric Nephrology, Tokyo Women's Medical University of Tokyo Woman's UHP, said, "Soliris has been proven to have a life-transforming impact on patients suffering from aHUS and represents a significant step forward in the treatment of this devastating disease. Results from clinical studies show that chronic Soliris treatment inhibits complement-mediated TMA which is responsible for thrombosis, vital organ failure, and other life-threatening manifestations of aHUS." The Company expects that aHUS patients in Japan will commence treatment with Soliris during Q4 2013. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-19/ALXN] -- Opko Health Inc. Research Report On September 19, 2013, Opko Health Inc.'s (Opko) stock closing price fell slightly to $8.40, which is 0.9% lower than the previous day's closing price of $8.48. Earlier, on August 30, 2013, Opko had announced that the Company's 3.0% Convertible Senior notes due by 2033 are convertible by holders of such Notes into shares of the Company's Common Stock. On the day of this announcement, Opko's shares closed at $9.24. The Full Research Report on Opko Health Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-19/OPK] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. InvestorsReports.com SOURCE Investors' Reports Contact: Kristi Saunders, +1-315-982-6420 (North America)
Corporate Restructuring, Recognitions, Drug Approvals, Mergers and Stock Price Movements - Research Report on Agilent,
Press spacebar to pause and continue. Press esc to stop.